Bepirovirsen sodium
Highest phase reached
Phase 1
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Oligonucleotide
- Drug name
- Bepirovirsen sodium
- bepirovirsen sodium
- Bepirovirsen sodium
- BEPIROVIRSEN SODIUM [USAN]
- bepirovirsen sodium usan
- dna d p thio 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl m5rc 2 o 2 methoxyethyl ra 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl ra g g t g a a g m5c g a 2 o 2 methoxyethyl ra 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl m5ru 2 o 2 methoxyethyl rg 2 o 2 methoxyethyl m5rc sodium salt 1 19
- DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-G-G-T-G-A-A-G-M5C-G-A-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC), SODIUM SALT (1:19)
- gsk 3228836a
- GSK-3228836A
- gsk3228836a
- GSK3228836A
- isis 505358 sodium
- ISIS 505358 SODIUM
- ISIS-505358 SODIUM
- CAS registry numbers
- 2563929-84-8
- ChEMBL ID
- CHEMBL5095442
- FDA ingredient codes (UNII)
- XCC829VFT7
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -rsen; -vir-
Investigated indications
- Condition
- Hepatitis B
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004197
- Subject identifier
- D006509
- Condition identifier
- EFO_0004197
- Condition identifier
- MONDO_0005344
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (10)
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
- A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
- A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
- Bepirovirsen Liver Biopsy Study
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
- Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
- Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
In development for (1)
- Hepatitis B virus infection Phase 1